Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Probiodrug AG. (10/27/16). "Press Release: Probiodrug to Present at European Life Sciences Conferences. Attendance at Key Conferences in November 2016". Halle (Saale).

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Probiodrug AG (Euronext Amsterdam: PBD)
  Group Probiodrug (Group)
  Organisation 2 EBD Group AG (CH)
  Today EBD Group GmbH (DE)
  Group Informa Group (Group)
Products Product BIO-Europe 2016 Köln (Cologne)
  Product 2 Deutsches Eigenkapitalforum 2016 Frankfurt (German Equity Forum 2016)
Index terms Index term Probiodrug–Deutsche Börse: investor conference, 201611 supply service Probiodrug AG presents at Deutsches Eigenkapitalforum 2016
  Index term 2 Probiodrug–Leucadia: investor conference, 201611 supply service Probiodrug AG attends Jefferies Global Healthcare Conference London
Persons Person Glund, Konrad (Probiodrug 1997– Founder + CEO 2008)
  Person 2 Liebers, Hendrik (Probiodrug 2007c– CFO before IBG Sachsen-Anhalt Head Life Science before Sachsen LB)
     


Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that the company is scheduled to attend the following conferences:


(1) BIO Europe

7 – 9 November 2016, KoelnMesse – Congress Center North, Cologne, Germany

Dr Konrad Glund, CEO, to present on Wednesday, 9 November 2016, at 10:30 am CET in Rheinsaal 2 (level 2) and host meetings


(2) Jefferies 2016 London Healthcare Conference

16 – 17 November 2016, Waldorf Hilton, London, UK

Dr Hendrik Liebers, CFO, to attend and host meetings


(3) Biotech and Money Inv€$tival Showcase

18 November 2016, Waldorf Hilton, London, UK

Dr Hendrik Liebers, CFO, to present at 10:30 am GMT and host meetings


(4) Deutsches Eigenkapitalforum

21 – 23 November 2016, Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany

Dr Hendrik Liebers, CFO, to present on Monday, 21 November 2016, at 4:30 pm CET in Room Oslo and host meetings


###


For more information, please contact:

Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de

Hume Brophy
Supriya Mathur, Eva Haas, Alexia Faure
Tel: +44 (0) 20 7862 6475
Email: probiodrug@humebrophy.com

The Trout Group
Tricia Truehart
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com


Notes to Editors:

About Probiodrug AG

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.

Probiodrug’s lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in Alzheimer’s animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition.

www.probiodrug.de


About Alzheimer’s disease

Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. . Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer’s also has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).


Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

   
Record changed: 2017-07-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Probiodrug (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px